drugset

drugset / Trial / NCT04316624

A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy

NCT04316624 ↗

Phase 1 Completed 7 enrolled Institute of Hematology & Blood Diseases Hospital, China Shanghai AbelZeta Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR066 in treatment of r/r DLBCL who received CD19 CAR-T therapy.

Timeline

Start: 2019-09-29
Primary completion: 2023-02-08
Completion: 2023-02-08

Publications

Li P, Liu W, Zhou L, Ye S, Zhu D, Huang J, Li J, Zheng C, Zhu S, Yao X, Zhu K, Yao Y, Qiu L, Liang A, Zou D. C-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy: A phase I clinical study. Am J Hematol. 2024 Dec;99(12):2306-2312. doi: 10.1002/ajh.27488. Epub 2024 Oct 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	C-CAR066	Cell therapy	2e+06 cells/kg	Intravenous
Subject	C-CAR066	Cell therapy	3e+06 cells/kg	Intravenous

Indications